135 results about "Tachycardia" patented technology

The invention relates to the technical field of medical and industrial cross, in particular to a method and device for generating a dynamic cardiac electrical excitation diagram, and the method comprises the steps: carrying out the phase alignment of the electrical excitation diagram and the cardiac image data of a preset mode, and obtaining time domain alignment data; on the basis of the time domain alignment data, aligning the heart models reconstructed in different modes according to the anatomical form to obtain space domain alignment data; and projecting an electrical mapping result to a corresponding anatomical structure of the heart based on the time domain alignment data and the spatial domain alignment data, and constructing a dynamic heart model of individualized electrical anatomical mapping of the target patient so as to display propagation of the electrical excitation diagram in the whole cardiac cycle on the dynamic heart model according to the conduction velocity in one cardiac cycle. According to the method, the dynamic heart model of the individualized electroanatomical mapping of the specific patient can be constructed by using the cardiac electrophysiology and anatomical structure data, the dynamic cardiac electrical excitation diagram of the human body is reconstructed, and the catheter ablation treatment of the tachycardia patient is guided by using the dynamic cardiac electrical excitation diagram.

The present disclosure relates to a RF ablation catheter for septal reduction therapy having a cooling effect, and more particularly, to a RF ablation catheter for septal reduction therapy that is for performing RF ablation, in which RF energy is applied to an interventricular septum, for septal reduction therapy such as therapy for hypertrophic cardiomyopathy, which is a disease in which an interventricular septum of the left ventricle of the heart of the animal or human body thickens, therapy that requires reduction of an interventricular septum, or therapy for ventricular tachycardia. Also, the present disclosure relates to a RF ablation catheter for septal reduction therapy having a cooling effect that is for preventing carbonization of a tissue of the body (interventricular septum) around an electrode.An exemplary embodiment of the present disclosure provides a RF catheter for septal reduction therapy, the RF catheter including: an intra-septal part in which a tapered tip which becomes thinner toward an end thereof is formed at an end of a distal part and one or more electrodes are formed at positions on an outer circumferential surface that are adjacent to the tip; and a body part which is made of a soft material and has a guidewire lumen which passes through the intra-septal part from an inlet formed at the center of the end of the tip and has an outlet formed in a side surface, a coolant inlet lumen which is connected from a proximal part to an inner portion of the intra-septal part to allow a coolant to be injected from the outside and which has an open end, and a coolant outlet lumen which communicates with the coolant inlet lumen and has an exit formed in a side surface, wherein the guidewire lumen and the coolant inlet lumen do not communicate with each other and are partitioned from each other.

The present invention relates to a radiofrequency electrode ablation catheter for ventricular septal therapy with a cooling function, which is used for performing radiofrequency electrode ablation and has a cooling function for preventing carbonization of body (ventricular septum) tissue around the electrode, wherein radiofrequency energy is applied to the ventricular septum during radiofrequency electrode ablation to perform ventricular septal therapy (e.g., therapy for hypertrophic cardiomyopathy, a disease in which the left ventricular septum of the heart of an animal or human body becomes thickened, therapy requiring reduction of the ventricular septum, or ventricular tachycardia, etc.). The radiofrequency catheter for ventricular septal therapy according to a preferred embodiment of the present invention includes a septal insertion portion and a body portion.

The invention relates to the technical field of nutritional supplements. A traditional fat reducing method mainly comprises dieting, high-intensity exercise, medicine weight losing and the like. However, dieting may lead to malnutrition; high-intensity sports are difficult to insist, and sports injury is easily caused; in order to solve the technical problems, the invention discloses a fat-reducing nutritional composition capable of improving metabolism, and the fat-reducing nutritional composition can be used for solving the technical problems of severe side effects such as tachycardia, insomnia and the like caused by medicine weight loss. The composition comprises the following components in parts by weight: 13-21 parts of a bitter gourd extract, 15-31 parts of a garcinia cambogia extract, 13-17 parts of oat fibers, 17-23 parts of whey protein powder, 7-9 parts of linseed oil, 6-14 parts of a green tea extract, 9-15 parts of a calcium supplement and 15-19 parts of a purple perilla seed extract, and can provide energy for a user, supplement immune globulin, lactoferrin and a calcium source, improve the immunity of the user and improve the immunity of the user. The body metabolism level and immunocompetence are improved, absorption of fat in digestive tracts can be effectively inhibited, storage of fat in the body is reduced, fat consumption is promoted, and the fat reducing effect is achieved.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine compound composition with a treatment effect on rapid atrial fibrillation and a preparation method of the traditional Chinese medicine compound composition. The traditional Chinese medicine composition comprises radix pseudostellariae, rhizoma polygonati, radix rehmanniae preparata, radix paeoniae alba, spina date seed, mulberry, jujube kernel, schisandra chinensis, Huai wheat, radix ophiopogonis, ligusticum wallichii, salvia miltiorrhiza, radix rehmanniae, coptis chinensis, radix paeoniae rubra, liquorice, fingered citron, calcined dragon bone, calcined oyster shell and rose. The invention aims at the basic pathogenesis of rapid atrial fibrillation dialectically belonging to insufficiency of heart yin, deficiency of essence and blood, unsmooth emotion, blood vessel stasis, stasis depression and fever which are caused by tachycardia and irregular pulse and rhythm. The clinical research proves that the traditional Chinese medicine compound composition can obviously reduce the recurrence frequency and recurrence rate of patients suffering from paroxysmal rapid atrial fibrillation and improve the symptoms of palpitation, chest distress, palpitation and the like of rapid atrial fibrillation, and has the advantages of good clinical curative effect and wide application prospect. The defects of western medicines can be well overcome.

An apparatus and methods for performing ablation of myocardial tissues are disclosed. The apparatus includes a plurality of ablation electrode configurations to which nanosecond pulsed electric fields are applied. The methods relate to therapies to treat cardiac arrhythmias, such as, atrial fibrillation and scar-related ventricular tachycardia, amongst others. The affected myocardial tissues are ablated creating a plurality of lesions enabled by the nanosecond pulsed electric fields applied to either penetrating electrodes, endo-endo electrodes, or endo-epi electrodes. Different electrophysiological tests are performed to assess the application of nanosecond pulsed electric field ablation to specific desired tissue location within the heart. Test results show the potential to overcome limitations of current ablation therapies, thereby providing patients and doctors a superior treatment for cardiac arrhythmias.

In one embodiment, a method to diagnose a heart condition by a wearable cardioverter defibrillator is described. The method includes obtaining a signal from the at least one sensor and analyzing the signal from the at least one sensor into usable data. The method including calculating a measured heart rate and a consistency metric from the usable data. The method further including determining when the measured heart rate satisfies a heart rate threshold and determining when the consistency metric satisfies a consistency threshold. The method including diagnosing a slow PVT episode based at least in part on the heart rate threshold and consistency threshold being satisfied.

The present disclosure provides methods, systems and devices for guiding, a treatment of a patient experiencing sudden cardiac arrest, by a responder and / or a mechanical CPR device, in accordance with a patient specific treatment protocol. This protocol conditionally implements a pulseless electrical activity protocol when a rhythm classification of an electrocardiogram of the patient is a non-shockable cardiac rhythm with electrical activity and a pulse indication is the absence of the pulse of the patient, or an asystole protocol when the rhythm classification of the electrocardiogram of the patient is a non-shockable cardiac rhythm without electrical activity, or a return of spontaneous circulation protocol when the rhythm classification of the electrocardiogram of the patient is the non-shockable cardiac rhythm with electrical activity and the pulse indication is the presence of the pulse of the patient, or a ventricular fibrillation / ventricular tachycardia protocol when the rhythm classification of the electrocardiogram of the patient is a shockable cardiac rhythm.

Disclosed herein are implantable medical devices and systems, and methods for used therewith, that selectively perform atrial overdrive pacing while an intrinsic atrial rate of a patient is within a specified range.

Substernal implantable cardioveter-defibrillator (ICD) systems and methods for providing substernal electrical stimulation therapy to treat malignant tachyarrhythmia, e.g., ventricular tachycardia (VT) and ventricular fibrillation (VF) are described. In one example, an implantable cardioveter-defibrillator (ICD) system includes an ICD implanted in a patient and an implantable medical electrical lead. The lead includes an elongated lead body having a proximal end and a distal portion, a connector at the proximal end of the lead body configured to couple to the ICD, and one or more electrodes along the distal portion of the elongated lead body. The distal portion of the elongated lead body of the lead is implanted substantially within an anterior mediastinum of the patient and the ICD is configured to deliver electrical stimulation to a heart of the patient using the one or more electrodes.

Described herein are apparatuses and methods to detect tachycardias and selectively reject false tachycardia detections due to T-wave oversensing or noise. An apparatus includes electrodes, a sensing circuit coupled to at least two of the electrodes and configured to sense a signal indicative of cardiac electrical activity, and a smoothing filter configured to filter to the sensed signal indicative of cardiac electrical activity to thereby produce a filtered signal indicative of cardiac electrical activity. The apparatus produces a difference signal indicative of cardiac electrical activity by determining a difference between the sensed and filtered signals indicative of cardiac electrical activity. The apparatus also includes at least one processor configured to detect a tachycardia, or to determine whether or not to reject a tachycardia detection, based on the difference signal. The smoothing filter and / or difference circuitry can be implemented by the at least one processor, and / or other circuitry.

The invention concerns the use of compounds represented by formula (I)as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

A method includes applying pacing to ventricle of heart of patient from multiple electrode locations over circumference of multi-electrode catheter area. Cardiac signals are received in response to the pacing. A correlation algorithm is applied to the received signals to calculate a plurality of correlations among the received signals. Based on calculated correlations, the area is checked if it includes an arrhythmogenic location identified with predefined sufficient spatial resolution. If the resolution is insufficient, sub-area to pace is defined. Subsequent pacing is applied to ventricle from multiple electrode locations over a circumference of the sub-area. Subsequent cardiac signals are received in response to the subsequent pacing. Subsequent correlations among the subsequent received signals are calculated. Based on the subsequent correlations, it is ascertained whether the arrhythmogenic location is found in the sub-area. If an arrhythmogenic location is found with sufficient spatial resolution, the identified arrhythmogenic location is indicated to user.

The invention relates to a construction method and application of a spontaneous and persistent ventricular tachycardia animal model, in particular to a spontaneous and persistent ventricular tachycardia rat model based on MYL4 gene defect and myocardial infarction induction. The model is constructed by utilizing the synergistic effect of double pathological factors of MYL4 gene conserved gene defects and acquired myocardial infarction, the induction rate of the model is greater than or equal to 90%, the spontaneous duration time reaches 1-3 min, and the method is obviously superior to an existing construction method for inducing the spontaneous and continuous ventricular tachycardia model. The model can simulate the pathophysiological process of ventricular tachycardia after human MYL4 gene related cardiovascular diseases combined with myocardial infarction, provides general technical support for ventricular arrhythmia pathogenesis research, drug screening and medical instrument research and development, and has wide scientific research and clinical transformation value.

VfA cardiac therapy uses an implantable medical device or system. The implantable medical device includes a tissue piercing electrode that is implanted from the Koch triangle area of the right atrium through the right atrial endocardium and the central fibrous body into the basal region and / or septal region of the left ventricular myocardium of the patient's heart. The device may include a right atrial electrode, a right atrial motion detector, or both. The device may be fully implanted within the patient's heart or one or more leads may be used to implant the electrodes into the patient's heart. The device may be used to provide cardiac therapy, including single chamber or multi-chamber pacing, atrioventricular synchronous pacing, asynchronous pacing, triggered pacing, cardiac resynchronization pacing, or tachycardia-related therapy. Separate medical devices may be used to provide some of the functions for cardiac therapy, such as sensing, pacing, or shock therapy.

A method and medical device for detecting a cardiac event that includes sensing cardiac signals from a plurality of electrodes, the plurality of electrodes forming a first sensing vector and a second sensing vector, identifying the cardiac event as one of a shockable event and a non-shockable event in response to first processing of a first interval sensed along the first sensing vector during a predetermined sensing window and a second interval simultaneously sensed along the second sensing vector, performing second processing of the first interval and the second interval, different from the first processing, in response to the cardiac event being identified as a shockable event, and determining whether to delay identifying the cardiac event being shockable in response to the second processing of the first interval and the second interval.

A catheter utilizes a distal electrode array configured for quantification of endocardial or epicardial propagation velocity, with electrodes defining approximately equilateral triangles, such that the calculated velocity can be approximated regardless of the wave front direction. The distal electrode array can also include resilient splines carrying the electrodes such that the splines can deform to ensure contact between the electrodes and the heart tissue. Additionally, the electrodes of the distal electrode array can be individually addressable. Bipolar ablation lines or boxes can also be implemented using two parallel catheters at the endocardium and at the epicardium. Certain configurations include one or more distal electrode arrays of sufficient size to span an entire ventricular tachycardia (VT) circuit. The catheter may also be configured to detect block lines by pacing from edge pacing electrodes of the distal electrode array, and / or to detect fiber orientation by pacing from several edge pacing electrodes.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The utility model discloses a rehabilitation auxiliary blowing assembly which comprises a blowing pipe and further comprises a blowing assembly body arranged on the blowing pipe and used for supraventricular tachycardia treatment, the blowing assembly body comprises a blowing opening and a connecting pipe which are installed at the front end and the rear end of the blowing pipe in a communicated mode, and an installation pipe is fixedly arranged on the outer side of the blowing pipe in a communicated mode. A balloon is detachably mounted on the mounting pipe through a limiting assembly. According to the rehabilitation assisting air blowing assembly, in the process of supraventricular tachycardia treatment and rehabilitation through the air blowing assembly, chest pressure is increased through the air blowing process, blood circulation and autonomic nerve function states are affected, the effect of supraventricular tachycardia treatment and rehabilitation is further achieved, and in the whole treatment process, the recovery effect is improved, and the recovery rate of supraventricular tachycardia is increased. The treatment effect is ensured, and meanwhile, the treatment effect can be visually judged conveniently through deformation of the balloon and display of the pressure gauge.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

This disclosure is directed to systems and techniques for determining an evidence level of an atrial tachycardia (AT) episode based on heart beat intervals in the cardiac activity data over a pre-determined time period. Based on a determination that the evidence level indicates relatively regular heart beat intervals, the example techniques apply a first set of AT detection criteria and indicate a detection of an AT episode based on satisfaction of at least one of the first set of AT detection criteria. Based on a determination that the evidence level indicates relatively irregular heart beat intervals, the example techniques apply a second set of AT detection criteria and indicate a detection of an AT episode based on based on satisfaction of at least one of the second set of AT detection criteria.

The invention discloses a sweat and heart rate detection integrated multi-mode flexible sensor, a preparation method and a detection system. The sweat and heart rate detection integrated multi-mode flexible sensor comprises a multi-mode flexible sensor patch and a collector, the multi-mode flexible sensor patch comprises a release film layer, a skin glue layer, an electrode layer, a flow channel layer and a film covering layer which have the same main body shape and are arranged in sequence, and the collector is fixed on the upper surface of the multi-mode flexible sensor patch and is electrically connected with the multi-mode flexible sensor patch. The multi-mode flexible sensor integrates a sweat detection sensor and a heart rate detection sensor (ECG sensor), sweat and the heart rate can be detected at the same time, electrolyte unbalance in the sweat may be accompanied by heart rate abnormity (such as tachycardia caused by hypokalemia), the diagnosis accuracy can be improved through combined monitoring, and the diagnosis efficiency is improved. More comprehensive physiological information can be provided for the user through physiological indexes (sweat), cardiac functions (ECG) and behavior data (movement and sleep).

The invention concerns the use of compounds represented by formula (I)as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

A system includes a catheter, an electrocardiogram (ECG) system, and a processor. The catheter is configured to apply pacing to a given tissue location inside a ventricle of a heart of a patient. The ECG system is configured to acquire a set of ECG signals generated in response to the pacing, wherein electrodes of the ECG system attached to the patient define respective directions in space with respect to an origin located in the heart. The processor is configured to (i) compute a set of respective signal differences between the acquired set of ECG signals and a reference set of ECG signals, (ii) compute a set of corresponding deviation vectors along the respective directions in the space, the deviation vectors having magnitudes corresponding to the respective signal differences, (iii) using the deviation vectors, compute a direction vector from the given location to a new ventricle location at which to apply the pacing, and (iv) indicate the computed direction vector to a user.

The system described herein includes a tool that has been developed for the interactive planning of therapies (e.g., ablation therapies such as RA in the treatment of VT or catheter- based therapies, among many others) by accurately registering all treatment planning images into the same frame-of-reference, to enable physician interaction with different image visualizations of these registered images, including ablation target selection, to provide an environment that facilitates the efficient and accurate exchange of knowledge between physicians. The proposed tool is provided to increase access, expedite delivery, and improve target accuracy for various therapies, including the non-limiting example described below which provides an innovative non-invasive VT ablation therapy.

The present patent application relates to a formulation capable of improving tolerance to stressful situations and the ability to concentrate and memory, while limiting or eliminating side effects such as anxiety, tachycardia, and sleep disorders.

The method includes acquiring intracardiac unipolar and intracardiac bipolar signals at a given region of the patient's heart. The unipolar signals are pruned by removing those unipolar signals that correspond in time to the respective bipolar signals. One or more unipolar signals are identified from among the pruned unipolar signals that are associated with far-field P-waves. Using the identified P-waves, a window of interest (WOI) is established on an electrogram acquired within the atrium of the heart, and the electrogram with the established WOI is used to generate an electrophysiological (EP) map of the atrium indicative of atrial tachycardia (AT) tissue location therein.